RxDoctor Payments Data

Basel Baghal, DO

Internal Medicine · Maywood, NJNPI 1356703409

Payments from drug & device makers

$1,110in general payments, 2019–2025

Across 74 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$627
  • Gilead$102
  • GSK$59
  • Lilly USA, LLC$55
  • Amarin Pharma, Inc.$40
  • Pfizer$38
  • plus $190 from 8 others

What the payments were for

  • Food & beverage$1,110100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,110 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$47,998
Medicare patients
131
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin127$141,875
OzempicSemaglutide107$112,259
RybelsusSemaglutide45$73,777
EliquisApixaban83$57,147
FarxigaDapagliflozin Propanediol21$31,086
JanuviaSitagliptin Phosphate18$25,407
LinzessLinaclotide22$19,966
TradjentaLinagliptin17$14,031
VascepaIcosapent Ethyl28$13,438
XareltoRivaroxaban16$13,166
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,324
BrilintaTicagrelor11$10,606
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,231
DuleraMometasone/Formoterol17$7,046
SynjardyEmpagliflozin/Metformin Hcl11$6,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$627$186,037152 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$13$161,916155 claims
PfizerEliquis$38$57,14783 claims
MerckJanuvia, Dulera$38$32,45335 claims
Johnson & JohnsonXarelto$14$13,16616 claims
GSKTrelegy Ellipta$59$12,32417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Maywood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →